Drug Trial Radar · NCT07628049
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,456
Planned (sponsor's estimate)
Start
Jun 5, 2026
Primary completion
Apr 5, 2029
Study completion Apr 5, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Conditions
- Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccineBiological
RSV/hMPV\_V low dose vaccine administered intramuscularly.
RSV/hMPV_V medium dose vaccineBiological
RSV/hMPV\_V medium dose vaccine administered intramuscularly.
RSV/hMPV_V high dose vaccineBiological
RSV/hMPV\_V high dose vaccine administered intramuscularly.
RSV/hMPV_W low dose vaccineBiological
RSV/hMPV\_W low dose vaccine administered intramuscularly.
RSV/hMPV_W medium dose vaccineBiological
RSV/hMPV\_W medium dose vaccine administered intramuscularly.
RSV/hMPV_W high dose vaccineBiological
RSV/hMPV\_W high dose vaccine administered intramuscularly.
RSV/hMPV_X low dose vaccineBiological
RSV/hMPV\_X low dose vaccine administered intramuscularly.
RSV/hMPV_X medium dose vaccineBiological
RSV/hMPV\_X medium dose vaccine administered intramuscularly.
RSV/hMPV_X high dose vaccineBiological
RSV/hMPV\_X high dose vaccine administered intramuscularly.
hMPV_Y low dose vaccineBiological
hMPV\_Y low dose vaccine administered intramuscularly.
hMPV_Y medium dose vaccineBiological
hMPV\_Y medium dose vaccine administered intramuscularly.
hMPV_Y high dose vaccineBiological
hMPV\_Y high dose vaccine administered intramuscularly.
hMPV_Z low dose vaccineBiological
hMPV\_Z low dose vaccine administered intramuscularly.
hMPV_Z medium dose vaccineBiological
hMPV\_Z medium dose vaccine administered intramuscularly.
hMPV_Z high dose vaccineBiological
hMPV\_Z high dose vaccine administered intramuscularly.
Control vaccineBiological
Control vaccine administered intramuscularly.
PlaceboCombination product
Placebo administered intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Solicited Administration Site EventsTime frame: Day 1 to Day 7
- Number of Participants Reporting Solicited Systemic EventsTime frame: Day 1 to Day 7
- Number of Participants Reporting Unsolicited Adverse Events (AEs)Time frame: Day 1 to Day 30
- Number of Participants Reporting Medically Attended Adverse Events (MAAEs)Time frame: Day 1 to Month 12
- Number of Participants Reporting Potential immune-mediated disorders (pIMDs)Time frame: Day 1 to Month 12
- Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to study end [Month 24 for OA groups (only the selected formulation group & its comparators) and Month 12 for all other YA groups & OA groups]
- Number of Participants Reporting Hematological and Biochemical Laboratory AbnormalitiesTime frame: At Day 1 (pre-vaccination) in Phase 1 groups
- Number of Participants Reporting Hematological and Biochemical Laboratory AbnormalitiesTime frame: At Day 8 (post-vaccination) in Phase 1 groups
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Stockbridge, Georgia · Recruiting
GSK Investigational Site
Lenexa, Kansas · Recruiting
GSK Investigational Site
Seattle, Washington · Recruiting
GSK Investigational Site
Botany, New South Wales, Australia · Recruiting
GSK Investigational Site
Camberwell, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.